ARTICLE | Company News
Merck KGaA neurology news
April 15, 2013 7:00 AM UTC
The Merck Serono S.A. division of Merck launched Asceneuron S.A. (Geneva, Switzerland) to develop the division's preclinical Alzheimer's disease (AD) programs targeting microtubule-associated protein-tau (MAPT; TAU, FTDP-17) and beta amyloid. Asceneuron will develop the programs up to Phase I testing and seek a partnership or licensing deal for further development. Merck Serono will invest €5 million ($6.4 million) in seed funding, and Merck Serono Ventures will manage the investment. The company will employ eight current Merck Serono employees. ...